[51]
Novopharm also says that Prothonotary Milczynski was also clearly wrong in holding that Mr. Windross' evidence was general, vague and speculative in comparison with that of Dr. Liston. In fact, Novopharm alleges it was Dr. Liston who speculated on what might or might not be in Novopharm's ANDS. Mr. Windross, on the other hand, gave detailed and specific evidence about the confidentiality of the documents in question and the harm that would be suffered by Novopharm if those documents were made public.